Micro-cap intelligence for the people who move capital and make decisions.
The Daily MicroCap
The Daily MicroCap — micro-cap news, market analysis, and daily briefings for investors.
Micro-cap intelligence. Signal over hype. Clarity over complexity.
Just Published
Latest Intelligence
The $465M Cancer Biotech Coming for AstraZeneca's Crown: BlossomHill's Nasdaq Debut
BlossomHill Therapeutics (BLSM) — a San Diego-based clinical-stage oncology biotech with $257M raised pre-IPO, a founder with three FDA-approved drugs, and a lead EGFR inhibitor targeting the C797S resistance mutation Tagrisso can't touch — goes public at ~$465M valuation via a J.P. Morgan-led syndicate.
The $75M Bet on a Drug No One's Heard Of: Inside Vogenx's Nasdaq Debut
Vogenx (VOGX) — a Raleigh-based clinical-stage biotech with four employees and $251K cash — goes public at ~$173M valuation with mizagliflozin, an SGLT1 inhibitor for post-bariatric hypoglycemia, a condition with zero FDA-approved therapies.
The Holding Company Behind PatentVest: Why MDB Capital's Portfolio May Be Worth More Than Its Market Cap
MDB Capital Holdings (NASDAQ: MDBH) is a publicly traded venture platform whose portfolio of equity stakes — including eXoZymes and Paulex Bio — plus $22.3M in net assets may exceed its entire $32M market cap. With PatentVest, its AI-enabled IP intelligence subsidiary, planning a spin-off and a Paulex Bio IPO targeted for September 2026, the next 12 months could test whether the sum of the parts exceeds the whole.
The Quiet Turnaround: How Bill Crossland Rebuilt Thermal Energy International
Thermal Energy International (TSX-V: TMG, OTCQB: TMGEF) has grown revenue every year since 2022 under long-tenured CEO Bill Crossland, with recent quarters showing 62% revenue growth and tripled adjusted EBITDA. At under 1x EV/Revenue, the market has not yet priced in the multi-year growth trend.
Micro-Cap Index Close: August 6, 2026 — Seven Benchmarks, One Ugly Day for Earnings Losers
The Russell Microcap Index is up 58.5% over the past year, but August 6 was an earnings-driven bloodbath for individual micro-caps. ThredUp (TDUP) got cut in half after dropping guidance, while Oportun Financial (OPRT) surged 33% on a Q2 beat. Here's how all seven benchmark indexes performed and the top 5 winners and losers in the $50M–$500M range.
Top Signal Stories
Featured Intelligence
A $29M Company Is Trying to Close a $1.5 Billion Deal by July 31. No More Extensions.
Diginex (NASDAQ: DGNX) — market cap under $30 million — has a signed definitive agreement to acquire Resulticks for $1.5 billion in an all-share deal. The hard deadline is July 31. No further extensions. Here's what's actually happening.
The Great Rotation Is Real. The Numbers Prove It.
The Russell Microcap Index is up 58.5% over the past year. The Russell Top 50 — the mega-cap benchmark — is up 2.0% over the same period. This is not a trade. It is a regime change. Here is what is driving it and what it means for investors in this space.
Bimergen Energy's Battery Storage Story Has a Paid-Promotion Problem
Bimergen Energy touts a 2.0 GW battery storage pipeline and a path to $400M in revenue — but the company has zero revenue today, is on its seventh reverse stock split, pays for its own investor-relations coverage, and just diluted shareholders 38% in a year.
Section
Movers & Money Flow
Financings, valuations, public equity, and the capital flows shaping the micro-cap economy.
The Holding Company Behind PatentVest: Why MDB Capital's Portfolio May Be Worth More Than Its Market Cap
MDB Capital Holdings (NASDAQ: MDBH) is a publicly traded venture platform whose portfolio of equity stakes — including eXoZymes and Paulex Bio — plus $22.3M in net assets may exceed its entire $32M market cap. With PatentVest, its AI-enabled IP intelligence subsidiary, planning a spin-off and a Paulex Bio IPO targeted for September 2026, the next 12 months could test whether the sum of the parts exceeds the whole.
The Quiet Turnaround: How Bill Crossland Rebuilt Thermal Energy International
Thermal Energy International (TSX-V: TMG, OTCQB: TMGEF) has grown revenue every year since 2022 under long-tenured CEO Bill Crossland, with recent quarters showing 62% revenue growth and tripled adjusted EBITDA. At under 1x EV/Revenue, the market has not yet priced in the multi-year growth trend.
Micro-Cap Index Close: August 6, 2026 — Seven Benchmarks, One Ugly Day for Earnings Losers
The Russell Microcap Index is up 58.5% over the past year, but August 6 was an earnings-driven bloodbath for individual micro-caps. ThredUp (TDUP) got cut in half after dropping guidance, while Oportun Financial (OPRT) surged 33% on a Q2 beat. Here's how all seven benchmark indexes performed and the top 5 winners and losers in the $50M–$500M range.
Explainers
Explain This Like I'm Smart
No physics degree required. Just real explanations for smart people.
High Signal
Recent Intelligence
The $1B Non-Opioid Pain Play: Latigo's NEJM-Validated Nav1.8 Inhibitor Goes Public
Latigo Biotherapeutics (LTGO) — with $321M raised pre-IPO, Phase 2b data published in NEJM, FDA Fast Track designation, and a 52% opioid-free rate — goes public at ~$1B valuation to challenge Vertex's Journavx in the multibillion-dollar non-opioid pain market.
The $465M Cancer Biotech Coming for AstraZeneca's Crown: BlossomHill's Nasdaq Debut
BlossomHill Therapeutics (BLSM) — a San Diego-based clinical-stage oncology biotech with $257M raised pre-IPO, a founder with three FDA-approved drugs, and a lead EGFR inhibitor targeting the C797S resistance mutation Tagrisso can't touch — goes public at ~$465M valuation via a J.P. Morgan-led syndicate.
The Quiet Turnaround: How Bill Crossland Rebuilt Thermal Energy International
Thermal Energy International (TSX-V: TMG, OTCQB: TMGEF) has grown revenue every year since 2022 under long-tenured CEO Bill Crossland, with recent quarters showing 62% revenue growth and tripled adjusted EBITDA. At under 1x EV/Revenue, the market has not yet priced in the multi-year growth trend.
The First Blast Heard Across the Iron Range: Inside TMCR's Minnesota Royalty Play
The Metals Royalty Company (TMCR) just fired the first production blast at its Mesabi Metallics iron ore royalty asset — 211,000 tons of ore fractured in Minnesota's first new mine in 50 years. With a 2% gross overriding royalty on a $2.5 billion DR-grade pellet project, a $363M market cap, and a Diamond Equity price target of $20.35, TMCR is a micro-cap royalty play at the exact moment American iron ore is coming back.
Intelligence Database
Company Tracker
Micro-cap and small-cap companies across biotech, mining, energy, technology, and emerging sectors.
Daily Intelligence Product
The Daily MicroCap
The Daily MicroCap — micro-cap news, market analysis, and daily briefings for investors.
Delivered before market open. Free. No spam.
No spam. Unsubscribe anytime.